Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Requip 1 mg Film-coated Tablets
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Ropinirole hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for
ReQuip is used to treat Parkinson's disease. The active ingredient in ReQuip is ropinirole, which belongs to a group of medicines called dopamine agonists. Dopamine agonists affect the brain in a similar way to a natural substance called dopamine. People with Parkinson's disease have low levels of dopamine in some parts of their brains. Ropinirole has effects similar to those of natural dopamine, so it helps to reduce the symptoms of Parkinson's disease.
2
What you need to know before you take it
e ReQuip
Do not take ReQuip: • • •
if you are allergic to ropinirole or any of the other ingredients of this medicine (listed in section 6) if you have serious kidney disease if you have liver disease ➔ Tell your doctor if you think any of these may apply to you.
Warnings and precautions Talk to your doctor or pharmacist before taking ReQuip:
- if you are pregnant or think you may be pregnant
- if you are breast-feeding
- if you are under 18 years old
- if you have a serious heart complaint
- if you have a serious mental health problem
- if you have experienced any unusual urges and/or behaviours (such as excessive gambling or excessive sexual behaviour)
•
if you have an intolerance to some sugars (such as lactose).
Tell your doctor if you experience symptoms such as depression, apathy, anxiety, fatigue, sweating or pain after stopping or reducing your Requip treatment (called dopamine agonist withdrawal syndrome or DAWS). If the problems persist more than a few weeks, your doctor may need to adjust your dose. Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings, or aggressive behaviours. Your doctor may need to adjust or stop your dose. Tell your doctor if you or your family/carer notices that you are developing episodes of overactivity, elation or irritability (symptoms of mania). These may occur with or without the symptoms of impulse control disorders (see above). Your doctor may need to adjust or stop your dose. ➔ Tell your doctor if you think any of these may apply to you. Your doctor may decide that ReQuip isn't suitable for you or that you need extra check-ups while you're taking it.
Children Do not give ReQuip to children. ReQuip is not normally prescribed for people under 18.
Other medicines and ReQuip Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including any herbal remedies or other medicines you bought without a prescription. Some medicines can affect the way ReQuip works or make it more likely that you'll have side effects. ReQuip can also affect the way some other medicines work. These include:
- the anti-depressant fluvoxamine
- HRT (hormone replacement therapy)
- the antibiotics ciprofloxacin or enoxacin
- medication for other mental health problems, for example sulpiride
- metoclopramide, which is used to treat nausea and heartburn
- cimetidine, used in the treatment of stomach ulcers
- any other medicine for Parkinson's disease. ➔ Tell your doctor if you're taking, or have recently taken, any of these. Remember to tell your doctor if you start taking any other medicine while you're taking ReQuip.
ReQuip with food and drink If you take ReQuip with food, you may be less likely to feel sick or be sick (vomit). So it's best to take it with food if you can.
Pregnancy and breast-feeding ReQuip is not recommended if you are pregnant, unless your doctor advises that the benefit to you taking ReQuip is greater than the risk to your unborn baby. ReQuip is not recommended if you are breast-feeding, as it can affect your milk production. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor may advise you to stop taking ReQuip.
Driving and using machines ReQuip can make you feel drowsy. It can make people feel extremely sleepy and it sometimes makes people fall asleep very suddenly without warning.
Requip can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, do not drive or use machines. If you could be affected: don't drive, don't operate machines and don't put yourself in any situation where feeling sleepy or falling asleep could put you (or other people) at risk of serious injury or death. Don't take part in these activities until you are no longer affected. ➔ Talk to your doctor if this causes problems for you.
Important Information about some of the ingredients in ReQuip ReQuip contains lactose ReQuip tablets contain a small amount of a sugar called lactose. If you have an intolerance to lactose or any other sugars, ask your doctor for advice before you take ReQuip. ReQuip contains sodium ReQuip tablets contain less than 1 mmol sodium (23 mg) per tablet, that is to say essentially "sodiumfree".
Smoking and ReQuip Tell your doctor or nurse if you start smoking, or give up smoking, while you're taking ReQuip. Your doctor or nurse may need to adjust your dose.
3
How to take it
ReQuip
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. You may be given ReQuip on its own to treat the symptoms of your Parkinson's disease, or you may be given ReQuip as well as another medicine called L-dopa (also called levodopa). If you are taking L-dopa you may experience some uncontrollable movements (dyskinesias) when you first start taking ReQuip. Tell your doctor if this happens, as your doctor may need to adjust the dose of the medicines you are taking. Tell your doctor if you or your family notices that you are developing any unusual behaviours (such as an unusual urge to gamble or increased sexual urges and/or behaviours) while you are taking ReQuip. Your doctor may need to adjust or stop your dose.
How much ReQuip will you need to take? It may take a while to find out the best dose of ReQuip for you. The usual starting dose is 0.25 mg of ropinirole three times each day for the first week. Then your doctor will increase your dose each week, for the next three weeks. After that, your doctor will gradually increase the dose until you are taking the dose that is best for you. The usual is 1 mg to 3 mg three times each day (making a total daily dose of 3 mg to 9 mg). If your Parkinson's disease symptoms have not improved enough, your doctor may decide to gradually increase your dose some more. Some people take up to 8 mg of ReQuip three times a day (24 mg daily altogether). If you are also taking other medicines for Parkinson's disease, your doctor may advise you to gradually reduce the dose of the other medicine. Don't take any more ReQuip than your doctor has recommended. It may take a few weeks for ReQuip to work for you.
Taking your dose of ReQuip Take ReQuip three times a day.
Swallow your ReQuip tablets, with a glass of water. It's best to take ReQuip with food, because that makes it less likely that you'll feel sick (nauseous).
If you take more ReQuip than you should Contact a doctor or pharmacist immediately. If possible, show them the ReQuip pack. Someone who has taken an overdose of ReQuip may have any of these symptoms: feeling sick (nausea), being sick (vomiting), dizziness (a spinning sensation), feeling drowsy, mental or physical tiredness, fainting, hallucinations.
If you forget to take ReQuip Do not take a double dose to make up for a forgotten dose. Just take your next dose at the usual time. If you have missed taking ReQuip for more than a few days, ask your doctor for advice on how to start taking it again.
If you stop taking ReQuip Do not stop taking ReQuip without advice. Take ReQuip for as long as your doctor recommends. Don't stop unless your doctor advises you to. If you suddenly stop taking ReQuip your Parkinson's disease symptoms may quickly get much worse. A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk. The symptoms include: akinesia (loss of muscle movement), rigid muscles, fever, unstable blood pressure, tachycardia (increased heart rate), confusion, depressed level of consciousness (e.g. coma). If you need to stop taking ReQuip your doctor will reduce your dose gradually. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4
Possible side effects
Like all medicines, this medicine can cause side effects, although not everyone gets them. The side effects of ReQuip are more likely to happen when you first start taking it, or when your dose has just been increased. They are usually mild and may become less troublesome after you have taken the dose for a while. If you are worried about side effects, talk to your doctor.
Very common side effects: may affect more than 1 in 10 people
- fainting
- feeling drowsy
- feeling sick (nausea)
Common side effects: may affect up to 1 in 10 people
- hallucinations (sensing things that are not real)
- being sick (vomiting)
- feeling dizzy (a spinning sensation)
- heartburn
- stomach pain
- swelling of the legs, feet or hands
Uncommon side effects:
may affect up to 1 in 100 people
- feeling dizzy or faint, especially when you stand up suddenly (this is caused by a drop in blood pressure)
- low blood pressure (hypotension)
- feeling very sleepy during the day (extreme somnolence)
- falling asleep very suddenly without feeling sleepy first (sudden sleep onset episodes)
- mental problems such as delirium (severe confusion), delusions (unreasonable ideas) or paranoia (unreasonable suspicions)
- hiccups
Some patients may have the following side effects (frequency not known: cannot be estimated from the available data) • • • • • •
allergic reactions such as red, itchy swellings on the skin (hives), swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing, rash or intense itching (see section 2). aggression excessive use of ReQuip (craving for large doses of dopaminergic drugs in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome). depression, apathy, anxiety, lack of energy, sweating or pain may occur (called dopamine agonist withdrawal syndrome or DAWS) after stopping or reducing your Requip treatment. changes in liver function, which have shown up in blood tests spontaneous penile erection
You may experience the following side effects: •
•
inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:
- strong impulse to gamble excessively despite serious personal or family consequences.
- altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.
- uncontrollable excessive shopping or spending
- binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger) episodes of overactivity, elation or irritability
➔ Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms
If you are taking ReQuip with L-dopa People who are taking ReQuip with L-dopa may develop other side effects over time:
- uncontrollable movements (dyskinesias) are a very common side effect. Tell your doctor if this happens, as your doctor may need to adjust the doses of the medicines you are taking
- feeling confused is a common side effect
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5
How to store it
ReQuip
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and on the carton. The expiry date refers to the last day of that month. Do not store this medicine above 25°C. Keep in a dry place, away from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6
Contents of the pack and other information
What ReQuip contains The active substance in ReQuip is ropinirole (as the hydrochloride) as 0.25 mg, 1 mg, 2 mg or 5 mg tablets. The other ingredients are:
- tablet cores: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate
- film coats: 0.25 mg tablet: hypromellose, macrogol 400, titanium dioxide (E171), polysorbate 80 (E433). 1 mg tablet: hypromellose, macrogol 400, titanium dioxide (E171), iron oxide yellow (E172), indigo carmine aluminium (E132). 2 mg tablet: hypromellose, macrogol 400, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172). 5 mg tablet: hypromellose, macrogol 400, titanium dioxide (E171), indigo carmine aluminium (E132), polysorbate 80 (E433).
What ReQuip looks like and contents of the pack ReQuip (all strengths) is provided as pentagonal, film-coated tablets, marked 'SB' on one side. ReQuip 0.25 mg: white tablets marked '4890' on reverse side. ReQuip 1 mg: green tablets marked '4892' on reverse side. ReQuip 2 mg: pink tablets marked '4893' on reverse side. ReQuip 5 mg: blue tablets marked '4894' on reverse side. All strengths are supplied in blister packs. 0.25 mg strength carton contain 21 tablets and 1, 2 and 5 mg strength carton contain 84 tablets. The Marketing Authorisation Holder is SmithKline Beecham Limited, 79 New Oxford Street, London, WC1A 1DG, United Kingdom The Manufacturer is Glaxo Wellcome S.A., Avendia de Extremadura 3, 09400 Aranda de Duero, Burgos, Spain Other formats To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000 (UK Only) Please be ready to give the following information: Product name
ReQuip 0.25 mg ReQuip 1 mg ReQuip 2 mg ReQuip 5 mg
Reference number
10592/0085
This is a service provided by the Royal National Institute of Blind People.
This leaflet was last revised in June 2026. Trade marks are owned by or licensed to the GSK group of companies © 2026 GSK group of companies or its licensor
Frequently asked questions about Requip 1 mg Film-coated Tablets
How do I take Requip 1 mg Film-coated Tablets?
Requip 1 mg Film-coated Tablets comes as tablet containing 1mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Requip 1 mg Film-coated Tablets?
The active substance in Requip 1 mg Film-coated Tablets is ropinirole hydrochloride.
Are there equivalent medicines to Requip 1 mg Film-coated Tablets?
Medicines with the same active substance, strength and form include: Ropinirole 1 mg Film-coated Tablets, Ropinirole 1 mg film-coated tablets. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Requip 1 mg Film-coated Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Requip 1 mg Film-coated Tablets without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: ropinirole hydrochloride
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Treatment of Parkinson's Disease under the following conditions:
• Initial treatment as monotherapy, in order to delay the introduction of levodopa
• In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations)
4.2. Posology and method of administration
Oral use.
Adults
Individual dose titration against efficacy and tolerability is recommended.
Ropinirole should be taken three times a day, preferably with meals to improve gastrointestinal tolerance.
Treatment initiation: The initial dose should be 0.25 mg three times daily for 1 week. Thereafter, the dose of ropinirole can be increased in 0.25 mg three times daily increments, according to the following regimen:
Week
1
2
3
4
Unit dose (mg) of ropinirole
0.25
0.5
0.75
1.0
Total daily dose (mg) of ropinirole
0.75
1.5
2.25
3.0
Therapeutic regimen: After the initial titration, weekly increments of 0.5 to 1 mg three times daily (1.5 to 3 mg/day) of ropinirole may be given.
A therapeutic response may be seen between 3 and 9 mg/day of ropinirole. If sufficient symptomatic control is not achieved, or maintained after the initial titration as described above, the dose of ropinirole may be increased up to 24 mg/day.
Doses of ropinirole above 24 mg/day have not been studied.
If treatment is interrupted for one day or more re-initiation by dose titration should be considered (see above).
When ropinirole is administered as adjunct therapy to L-dopa, the concurrent dose of L-dopa may be reduced gradually according to the symptomatic response. In clinical trials, the levodopa dose was reduced gradually by around 20% in patients treated with ropinirole as adjunct therapy. In patients with advanced Parkinson's disease receiving ropinirole in combination with L-dopa, dyskinesias can occur during the initial titration of ropinirole. In clinical trials it was shown that a reduction of the L-dopa dose may ameliorate dyskinesia (see also section 4.8).
When switching treatment from another dopamine agonist to ropinirole, the manufacturer's guidance on discontinuation should be followed before initiating ropinirole.
As with other dopamine agonists, it is necessary to discontinue ropinirole treatment gradually by reducing the number of daily doses over the period of one week (see section 4.4).
Renal impairment:
In patients with mild to moderate renal impairment (creatinine clearance 30-50 ml/min) no change in the clearance of ropinirole was observed, indicating that no dosage adjustment is necessary in this population.
A study into the use of ropinirole in patients with end stage renal disease (patients on haemodialysis) has shown that a dose adjustment in these patients is required as follows: the initial dose of Requip should be 0.25 mg three times a day. Further dose escalations should be based on tolerability and efficacy. The recommended maximum dose is 18 mg/day in patients receiving regular haemodialysis. Supplemental doses after haemodialysis are not required (see section 5.2).
The use of ropinirole in patients with severe renal impairment (creatinine clearance less than 30 ml/min) without regular haemodialysis has not been studied.
Elderly: The clearance of ropinirole is decreased by approximately 15% in patients aged 65 years or above. Although a dose adjustment is not required, ropinirole dose should be individually titrated, with careful monitoring of tolerability, to the optimal clinical response.
Children and Adolescents: Requip is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy.
4.3. Contraindications
Hypersensitivity to ropinirole or to any of the excipients listed in section 6.1.
Severe renal impairment (creatinine clearance <30ml/min) without regular haemodialysis.
Hepatic impairment.
4.4. Special warnings and precautions for use
Psychiatric or psychotic disorders
Patients with major psychiatric or psychotic disorders, or a history of these disorders, should only be treated with dopamine agonists if the potential benefits outweigh the risks.
Somnolence and episodes of sudden sleep onset
Ropinirole has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson's Disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported uncommonly. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with ropinirole. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Furthermore, a reduction of dosage or termination of therapy may be considered.
Impulse control disorders
Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, aggressive behaviours, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including ReQuip. Dose reduction/tapered discontinuation should be considered if such symptoms develop.
Impulse control disorders were reported especially at high doses and were generally reversible upon reduction of the dose or treatment discontinuation. Risk factors such as history of compulsive behaviours were present in some cases (see section 4.8).
Mania
Patients should be regularly monitored for the development of mania. Patients and carers should be made aware that symptoms of mania can occur with or without the symptoms of impulse control disorders in patients treated with ReQuip. Dose reduction/tapered discontinuation should be considered if such symptoms develop.
Neuroleptic malignant syndrome
Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy. Therefore, it is recommended to taper treatment (see section 4.2).
Hypotension
Due to the risk of hypotension, blood pressure monitoring is recommended, particularly at the start of treatment, in patients with severe cardiovascular disease (in particular coronary insufficiency).
Dopamine agonist withdrawal syndrome (DAWS)
DAWS has been reported with dopamine agonists, including ropinirole (see section 4.8). To discontinue treatment in patients with Parkinson's disease, ropinirole should be tapered off (see section 4.2). Limited data suggests that patients with impulse control disorders and those receiving high daily dose and/or high cumulative doses of dopamine agonists may be at higher risk for developing DAWS. Withdrawal symptoms may include apathy, anxiety, depression, fatigue, sweating and pain and do not respond to levodopa. Prior to tapering off and discontinuing ropinirole, patients should be informed about potential withdrawal symptoms. Patients should be closely monitored during tapering and discontinuation. In case of severe and/or persistent withdrawal symptoms, temporary re-administration of ropinirole at the lowest effective dose may be considered.
Hallucinations
Hallucinations are known as a side effect of treatment with dopamine agonists and levodopa. Patients should be informed that hallucinations can occur.
Excipients
Lactose
This medicinal product also contains lactose.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Sodium
Each Requip film coated tablet contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium free'.
4.5. Interaction with other medicinal products and other forms of interaction
Neuroleptics and other centrally active dopamine antagonists, such as sulpiride or metoclopramide, may diminish the effectiveness of ropinirole and, therefore, concomitant use of these drugs with ropinirole should be avoided.
There is no pharmacokinetic interaction between ropinirole and L-dopa or domperidone which would necessitate dosage adjustment of these medicinal products.
Ropinirole is principally metabolised by the cytochrome P450 enzyme CYP1A2. A pharmacokinetic study (with a ropinirole dose of 2 mg, three times a day in patients with Parkinson's disease) revealed that ciprofloxacin increased the Cmax and AUC of ropinirole by 60% and 84% respectively, with a potential risk of adverse events. Hence, in patients already receiving ropinirole, the dose of ropinirole may need to be adjusted when medicinal products known to inhibit CYP1A2, e.g. ciprofloxacin, enoxacin, or fluvoxamine, are introduced or withdrawn.
A pharmacokinetic interaction study in patients with Parkinson's disease between ropinirole (at a dose of 2 mg, three times a day) and theophylline, substrate of CYP1A2, revealed no change in the pharmacokinetics of either ropinirole or theophylline
Increased plasma concentrations of ropinirole have been observed in patients treated with high doses of oestrogens. In patients already receiving hormone replacement therapy (HRT), ropinirole treatment may be initiated in the normal manner. However, if HRT is stopped or introduced during treatment with ropinirole, dosage adjustment may be required, in accordance with clinical response.
Smoking is known to induce CYP1A2 metabolism, therefore if patients stop or start smoking during treatment with ropinirole, adjustment of dose may be required.
4.6. Fertility, pregnancy and lactation
Pregnancy
There are no adequate data from the use of ropinirole in pregnant women. Ropinirole concentrations may gradually increase during pregnancy (see section 5.2).
Studies in animals have shown reproductive toxicity (see section 5.3). As the potential risk for humans is unknown, it is recommended that ropinirole is not used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the foetus.
Breast-feeding
Ropinirole-related material was shown to transfer into the milk of lactating rats. It is unknown whether ropinirole and its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded.
Ropinirole should not be used in nursing mothers as it may inhibit lactation.
Fertility
There are no data on the effects of ropinirole on human fertility. In female fertility studies in rats, effects were seen on implantation but no effects were seen on male fertility (see section 5.3).
4.7. Effects on ability to drive and use machines
Patients being treated with ropinirole and presenting with hallucinations, somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see also section 4.4 ).
4.8. Undesirable effects
Adverse events are listed below by system organ class and frequency. It is noted if these undesirable effects were reported in clinical trials as monotherapy or adjunct therapy to levodopa.
Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100), rare (≥1/10 000 to <1/1,000) very rare (<1/10 000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Immune system disorders
Not known:
Hypersensitivity reactions (including urticaria, angioedema, rash, pruritus.
Psychiatric disorders
Common:
hallucinations.
Uncommon:
psychotic reactions (other than hallucinations) including delirium, delusion, paranoia.
Not known:
aggression*, dopamine dysregulation syndrome, mania (see section 4.4), impulse control disorders** (see section 4.4.).
* Aggression has been associated with psychotic reactions as well as compulsive symptoms.
** Impulse control disorders: pathological gambling, increased libido, hypersexuality, aggression, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including ReQuip (see section 4.4).
Use in adjunct therapy studies:
Common:
confusion.
Nervous system disorders
Very common:
somnolence.
Common:
dizziness (including vertigo).
Uncommon:
sudden onset of sleep, excessive daytime somnolence.
Ropinirole is associated with somnolence and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes.
Use in monotherapy studies:
Very common:
syncope.
Use in adjunct therapy studies:
Very common:
dyskinesia. In patients with advanced Parkinson’s disease, dyskinesias can occur during the initial titration of ropinirole. In clinical trials it was shown that a reduction of the levodopa dose may ameliorate dyskinesia (see section 4.2)
Vascular disorders
Uncommon:
postural hypotension, hypotension.
Postural hypotension or hypotension is rarely severe.
Respiratory, thoracic and mediastinal disorders
Uncommon:
Hiccups
Gastrointestinal disorders
Very Common:
nausea.
Common:
heartburn.
Use in monotherapy studies
Common:
vomiting, abdominal pain.
Hepatobiliary disorders
Not known:
hepatic reactions, mainly increased liver enzymes.
Reproductive system and breast disorders
Not known:
Spontaneous penile erection
General disorders
Use in monotherapy studies:
Common:
oedema peripheral (including leg oedema).
Not known:
Dopamine agonist withdrawal syndrome (including apathy, anxiety, depression, fatigue, sweating and pain)
Dopamine agonist withdrawal syndrome
Non-motor adverse effects may occur when tapering or discontinuing dopamine agonists including ropinirole (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
The symptoms of ropinirole overdose are generally related to its dopaminergic activity. These symptoms may be alleviated by appropriate treatment with dopamine antagonists such as neuroleptics or metoclopramide.
💬 Ask about this leaflet
Ask anything about Requip 1 mg Film-coated Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
Medicines containing Ropinirole hydrochloride
- Adartrel 0.25 mg film-coated Tablets
- Adartrel 0.5 mg film-coated Tablets
- Adartrel 2.0 mg film-coated Tablets
- Ipinnia XL Prolonged-Release Tablets
- Repinex XL 2mg prolonged-release tablets
- Repinex XL 4mg prolonged-release tablets
- Repinex XL 8mg prolonged-release tablets
- Requip 0.25 mg Film-coated Tablets
- Requip 2 mg Film-coated Tablets
- Requip 5 mg Film-coated Tablets
- Ropinirole 0.25 mg film-coated tablets
- Ropinirole 0.5 mg film-coated tablets
- Ropinirole 1 mg Film-coated Tablets
- Ropinirole 2 mg Film-coated Tablets